Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab

Simple item page
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridUysal, Mukremin/0000-0002-8524-0665
dc.authoridUlas, Arife/0000-0003-2918-2592
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authoridSumbul, Ahmet T/0000-0002-5573-906X
dc.authoridaksoy, asude/0000-0002-5609-9658
dc.authorwosidbenekli, mustafa/AAE-4555-2020
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.authorwosidUysal, Mukremin/B-8956-2014
dc.authorwosidUlas, Arife/HGD-4686-2022
dc.authorwosidKucukoner, Mehmet/E-1162-2013
dc.authorwosidBAL, OZNUR/D-4160-2016
dc.authorwosidTanriverdi, Ozgur/M-2172-2015
dc.contributor.authorTonyali, Onder
dc.contributor.authorCoskun, Ugur
dc.contributor.authorYuksel, Sinemis
dc.contributor.authorInanc, Mevlude
dc.contributor.authorBal, Oznur
dc.contributor.authorAkman, Tulay
dc.contributor.authorYazilitas, Dogan
dc.date.accessioned2024-08-04T20:41:32Z
dc.date.available2024-08-04T20:41:32Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab. Methods: Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively. Results: Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER- and PR-) tumor (p = 0.001, RR: 3.4, 95% CI: 1.33-8.71) and stage 3 disease (p = 0.0032, RR: 9.39, 95% CI: 1.33-8.71) were significant risk factors for development of brain metastasis as the first site of recurrence. Conclusions: In patients with HER2 positive EBC who received adjuvant trastuzumab, HER2-enriched subtype (ER- and PR-) tumor and stage 3 disease were associated with increased risk of brain metastasis as the first site of disease recurrence. (C) 2015 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.breast.2015.11.006
dc.identifier.endpage26en_US
dc.identifier.issn0960-9776
dc.identifier.issn1532-3080
dc.identifier.pmid26801412en_US
dc.identifier.scopus2-s2.0-84959084796en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage22en_US
dc.identifier.urihttps://doi.org/10.1016/j.breast.2015.11.006
dc.identifier.urihttps://hdl.handle.net/11616/97191
dc.identifier.volume25en_US
dc.identifier.wosWOS:000368373500003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofBreasten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast canceren_US
dc.subjectAdjuvant therapyen_US
dc.subjectTrastuzumaben_US
dc.subjectBrain metastasisen_US
dc.titleRisk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumaben_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize